IMM01-STEM for Muscle Wasting in Knee Osteoarthritis
(STEM-MYO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called IMM01-STEM for muscle wasting in individuals with knee osteoarthritis. The goal is to determine if different doses of this treatment are safe and tolerable. Participants will receive various doses of IMM01-STEM through muscle injections twice a week for four weeks. Individuals with moderate knee osteoarthritis, noticeable quadriceps weakness, and the ability to walk over 50 feet without assistance may be suitable for this trial. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Do I have to stop taking my current medications to join the trial?
The trial requires that you stop using systemic oral or intravenous steroids for at least 6 months before joining. Additionally, you cannot take narcotic pain medication, local anti-inflammatory drugs, or other investigational drugs. If you've changed medications for conditions like diabetes or hypertension within a month before screening, you may not be eligible.
Is there any evidence suggesting that IMM01-STEM is likely to be safe for humans?
Research has shown that IMM01-STEM, a treatment for muscle wasting in knee osteoarthritis, has undergone safety testing in earlier studies. Initial results suggest that people generally tolerate the treatment well. In these studies, participants received varying doses of IMM01-STEM to assess their responses. Most participants did not experience serious side effects, indicating the treatment was generally safe for them.
However, as IMM01-STEM remains in the early testing stages, ongoing research is necessary to confirm its safety. This research is crucial for understanding and managing any potential side effects. Overall, early studies provide a positive view of the treatment's safety.12345Why do researchers think this study treatment might be promising for muscle wasting?
Most treatments for muscle wasting in knee osteoarthritis focus on pain relief and inflammation control, often using medications like NSAIDs or corticosteroids. Unlike these traditional methods, IMM01-STEM is unique because it directly targets muscle regeneration through intramuscular stem cell therapy. Researchers are excited about IMM01-STEM's potential to not just manage symptoms but to promote actual muscle repair and strengthening. This could lead to improved mobility and quality of life for patients, offering a fundamentally different approach compared to current treatments.
What evidence suggests that IMM01-STEM might be an effective treatment for muscle wasting in knee osteoarthritis?
Research has shown that IMM01-STEM may help with muscle loss in people with knee osteoarthritis. Early results from past studies suggest this treatment can reverse muscle loss, a common issue in this condition. Participants in those studies experienced improvements in muscle strength and function with IMM01-STEM. Importantly, no serious safety issues have been reported so far. These findings suggest that IMM01-STEM could effectively treat muscle wasting linked to knee osteoarthritis.34678
Who Is on the Research Team?
Tom Lane, PhD
Principal Investigator
Chief Science Officer at Immunis, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with moderate knee osteoarthritis and muscle weakness who can walk unassisted, have a BMI under 40, are not pregnant or breastfeeding, agree to use contraception, and do not have certain health conditions like severe liver disease or recent drug abuse. Participants must also be non-smokers for at least 10 years.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive twice weekly intramuscular administration of IMM01-STEM for 4 weeks
Safety Follow-up
Participants are monitored for safety with clinic visits 3 days after the last injection and then monthly for 3 months
What Are the Treatments Tested in This Trial?
Interventions
- IMM01-STEM
Trial Overview
The study tests the safety of IMM01-STEM in patients with muscle wasting due to knee osteoarthritis. It's an open-label trial where everyone gets the treatment; doses increase over time to find out what's safe.
How Is the Trial Designed?
4
Treatment groups
Active Control
Participants will receive twice weekly intramuscular (im) administration of IMM01-STEM for 4 weeks with a dose of 2000μg.
Participants will receive twice weekly intramuscular (im) administration of IMM01-STEM for 4 weeks with a dose of 450μg.
Participants will receive twice weekly intramuscular (im) administration of IMM01-STEM for 4 weeks with a dose of 225μg.
Participants will receive twice weekly intramuscular (im) administration of IMM01-STEM for 4 weeks with a dose of 900μg.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Immunis, Inc.
Lead Sponsor
Citations
STEM-META: Targeting Muscle Performance
Immunis is planning a Phase 2 placebo-controlled clinical trial to continue safety and efficacy assessments of IMM01-STEM on addressing muscle performance in ...
NCT06600581 | Safety and Efficacy of IMM01-STEM ...
Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness. ClinicalTrials.gov ID NCT06600581.
3.
ucihealth.org
ucihealth.org/about-us/news/2022/11/uci-opens-first-stem-cell-clinical-trial-to-treat-knee-arthritisUCI tests first stem cell therapy to treat knee arthritis
UCI Health and UCI Alpha Clinic have launched the first US clinical trial to test the safety and tolerability of IMM01-STEM in patients with knee ...
4.
immunisbiomedical.com
immunisbiomedical.com/news-media/press-releases/immunis-successfully-completes-its-phase-1-2a-clinical-trial-targeting-muscle-atrophy/Immunis Successfully Completes its Phase 1/2a Clinical ...
This parallel STEM-META program will focus on the efficacy of IMM01-STEM against a placebo on muscle and overall physical function in seniors ...
5.
clinicaltrialvanguard.com
clinicaltrialvanguard.com/news/immunis-achieves-breakthrough-in-muscle-atrophy-trial/Immunis Achieves Breakthrough in Muscle Atrophy Trial
... IMM01-STEM in reversing muscle atrophy in older adults with knee osteoarthritis. Initial data suggest positive outcomes with no reported ...
Safety and Tolerability of IMMUNA(IMM01-STEM) in ...
This will be an open-label, dose escalation study to assess the safety and tolerability of IMMUNA(IMM01-STEM), a secretome product derived from partially ...
7.
ctv.veeva.com
ctv.veeva.com/study/safety-and-tolerability-of-immuna-imm01-stem-in-patients-with-muscle-atrophy-related-to-knee-osteoaSafety and Tolerability of IMM01-STEM in Patients With ...
An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee ...
8.
c2c.uci.edu
c2c.uci.edu/vi/uci-opens-clinical-trial-of-stem-cell-derived-therapy-for-muscle-atrophy/UCI opens clinical trial of stem cell-derived therapy for muscle ...
... safety and tolerability of IMM01-STEM in patients with muscle atrophy related to knee osteoarthritis. Up to 18 patients ranging in age from 50 to 75 will be ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.